Clinical Trials Browser

Toremifene × Breast × Clear all

NCT05472792 2025-05-23

CAMERAN

Phase 2 Recruiting

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms

NCT05801705 2023-05-18

Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

Hormone-receptor-positive Breast Cancer

NCT04666805 2020-12-14

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT02344940 2019-09-24

TTOS

Phase 4 Completed

Breast Neoplasms

NCT02506790 2019-09-04

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Breast Cancer Organoids

NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Phase 4 Withdrawn

Breast Carcinoma In Situ, Breast Neoplasms

NCT03351062 2017-11-22

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Phase 4 Unknown

Triple Negative Breast Neoplasms

NCT02097459 2016-05-25

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Completed

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT02132390 2014-06-04

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

Phase 3 Unknown

Breast Neoplasms

NCT02132000 2014-05-06

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

Phase 2/3 Unknown

Breast Cancer Patients in Premenopausal

NCT00002529 2013-04-04

12-93

Phase 3 Completed

Breast Neoplasms

NCT00437359 2012-03-30

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT00267553 2007-09-10

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Phase 3 Terminated

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Phase 3 Terminated

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular